Uribe Alfredo, Giugliani Roberto
Centro de Investigaciones en Bioquimica (CIBI), Departamento de Ciencias Biologicas, Universidad de Los Andes, Carrera 1 No. 18A - 12 of. M-302, Bogota, Colombia,
JIMD Rep. 2013;11:107-16. doi: 10.1007/8904_2013_229. Epub 2013 Apr 23.
Lysosomal storage disorders (LSDs) are a very heterogeneous group of hereditary disorders. The diagnostic process usually involves complex sampling, processing, testing, and validation procedures, performed by specialized laboratories only, which causes great limitations in reaching a diagnosis for patients affected by these diseases.There are few studies about LSDs in Colombia. The diagnostic limitations often make medical practitioners disregard the possibility of these disorders while diagnosing their patients. The current study documents the results of a 7-year screening in high-risk patients, aimed to detect LSDs using dried blood spots (DBS) collected on filter paper, with a micromethodology that facilitates diagnosis even with a large number of samples.The activities of α-galactosidase A, α glucosidase, α-L-iduronidase, arylsulfatase B, β-galactosidase, β-glucosidase, total hexosaminidase, iduronate sulfatase, and chitotriosidase were analyzed in high-risk patients for lysosomal disease. The catalytic activity was evaluated with fluorometric micromethods using artificial substrates marked with 4-methylumbelliferone.The reference values for a control population were established for the enzymes listed above, and 242 patients were found to have an enzyme deficiency, guiding to the following diagnoses: Fabry disease (n = 31), Pompe disease (n = 16), Hurler Syndrome (n = 15), Maroteaux-Lamy Syndrome (n = 34), GM1 Gangliosidosis (n = 10), Morquio B (n = 1), Gaucher disease (n = 101), Sandhoff disease (n = 1), Mucolipidosis (n = 2), and Hunter Syndrome (n = 31). In conclusion, this protocol provides a comprehensive diagnostic approach which could be carried out in Colombia and made it available to medical services spread around the country, enabling the identification of a large number of patients affected by LSDs, which could potentially benefit from the therapeutic tools already available for many of these diseases.
溶酶体贮积症(LSDs)是一组遗传性疾病,种类繁多。诊断过程通常涉及复杂的采样、处理、检测和验证程序,且仅由专业实验室进行,这给这些疾病患者的诊断带来了很大限制。哥伦比亚关于LSDs的研究很少。诊断上的局限性常使医生在诊断患者时忽略这些疾病的可能性。本研究记录了对高危患者进行7年筛查的结果,旨在使用滤纸收集的干血斑(DBS)检测LSDs,采用的微量方法即便样本数量众多也便于诊断。对溶酶体疾病高危患者的α-半乳糖苷酶A、α-葡萄糖苷酶、α-L-艾杜糖醛酸酶、芳基硫酸酯酶B、β-半乳糖苷酶、β-葡萄糖苷酶、总己糖胺酶、艾杜糖醛酸硫酸酯酶和壳三糖苷酶的活性进行了分析。使用标记有4-甲基伞形酮的人工底物,通过荧光微量法评估催化活性。为上述酶建立了对照人群的参考值,发现242例患者存在酶缺乏,据此做出以下诊断:法布里病(n = 31)、庞贝病(n = 16)、Hurler综合征(n = 15)、马罗-拉米综合征(n = 34)、GM1神经节苷脂贮积症(n = 10)、莫尔基奥B病(n = 1)、戈谢病(n = 101)、桑德霍夫病(n = 1)、粘脂贮积症(n = 2)和亨特综合征(n = 31)。总之,该方案提供了一种全面的诊断方法,可在哥伦比亚实施并提供给全国各地的医疗服务机构,从而能够识别大量受LSDs影响的患者,这些患者可能会从针对其中许多疾病已有的治疗工具中受益。